FDA refuses application for cell therapy from Bristol and Bluebird

FDA refuses application for cell therapy from Bristol and Bluebird

STAT Plus: FDA refuses application for cell therapy from Bristol and Bluebird, dealing both a major setback

By MATTHEW HERPER

The decision by the FDA is a major setback for both companies, and could have implications for investors in Celenge, which was acquired by Bristol.

READ MORE